Iovance Biotherapeutics Files 2025 DEF 14A
Ticker: IOVA · Form: DEF 14A · Filed: Apr 28, 2025 · CIK: 1425205
| Field | Detail |
|---|---|
| Company | Iovance Biotherapeutics, Inc. (IOVA) |
| Form Type | DEF 14A |
| Filed Date | Apr 28, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, executive-compensation, board-of-directors
TL;DR
Iovance Biotherapeutics' 2025 DEF 14A is out, detailing exec pay and board changes.
AI Summary
Iovance Biotherapeutics, Inc. filed its DEF 14A on April 28, 2025, for the fiscal year ending December 31, 2024. The filing details executive compensation and board member information, including compensation for Frederick G. Vogt and Maria Fardis for the fiscal years 2021-2024. It also lists recent board appointments and changes effective March 5, 2025, for individuals like Raj K. Puri, M.D., Ph.D., and Jean-Marc Bellemin.
Why It Matters
This filing provides crucial details on executive and director compensation, offering insight into how Iovance Biotherapeutics incentivizes its leadership and governs its board.
Risk Assessment
Risk Level: medium — DEF 14A filings can reveal changes in executive compensation or board composition that may signal shifts in company strategy or governance, impacting investor confidence.
Key Numbers
- 2024 — Fiscal Year End (The filing covers compensation and governance for the fiscal year ending December 31, 2024.)
- 20250428 — Filing Date (This DEF 14A was filed on April 28, 2025.)
Key Players & Entities
- IOVANCE BIOTHERAPEUTICS, INC. (company) — Filer
- Frederick G. Vogt (person) — Executive/Board Member
- Maria Fardis (person) — Executive/Board Member
- Raj K. Puri, M.D., Ph.D. (person) — Board Member
- Jean-Marc Bellemin (person) — Board Member
- 20250428 (date) — Filing Date
- 2024-12-31 (date) — Fiscal Year End
FAQ
What is the primary purpose of this DEF 14A filing?
The primary purpose of this DEF 14A filing is to provide information regarding the solicitation of proxies for the company's annual meeting of stockholders, including details on executive compensation, board of directors, and corporate governance.
Who are some of the key individuals mentioned in relation to board membership or executive roles?
Key individuals mentioned include Frederick G. Vogt, Maria Fardis, Raj K. Puri, M.D., Ph.D., and Jean-Marc Bellemin, with their roles and compensation details provided for various fiscal years.
What fiscal years are covered by the compensation information provided?
The compensation information provided covers the fiscal years 2020 through 2024.
When was the company formerly known as Lion Biotechnologies, Inc. and Genesis Biopharma, Inc.?
The company was formerly known as Lion Biotechnologies, Inc. after a name change on October 15, 2013, and prior to that, as Genesis Biopharma, Inc. after a name change on March 19, 2010.
What is the business address and phone number for Iovance Biotherapeutics, Inc.?
The business address is 825 Industrial Road, 4th Floor, San Carlos, CA 94070, and the business phone number is 650-260-7120.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 28, 2025 by Frederick G. Vogt regarding IOVANCE BIOTHERAPEUTICS, INC. (IOVA).